Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a 30 mg tablet for oral use. It selectively antagonizes L‑type calcium channels in cerebral vessels, helping to prevent vasospasm after subarachnoid hemorrhage and to support treatment of other cerebrovascular disorders in adult patients under specialist care.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Nimotop (nimodipine) is indicated for conditions involving cerebral vasospasm and other cerebrovascular disorders.

- Subarachnoid hemorrhage (post‑aneurysmal): prevents delayed cerebral vasospasm and reduces risk of secondary ischemic injury. - Cerebral vasospasm (any etiology): induces vasodilation to improve cerebral blood flow and mitigate neurological deficits. - Cerebrovascular disorders (e.g., ischemic stroke adjunct): supports perfusion in affected brain regions as part of comprehensive therapy.

Nimotop may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache - Flushing - Nausea or vomiting - Dizziness or light‑headedness

Serious or Rare Side Effects: - Severe hypotension - Cardiac arrhythmias - Hepatic dysfunction (elevated transaminases)

When prescribing Nimotop, clinicians should consider several safety considerations to minimize risk.

- Indication verification: ensure use is limited to approved neurovascular conditions such as post‑hemorrhagic vasospasm. - Cardiovascular monitoring: observe blood pressure and heart rate, especially in patients with pre‑existing hypotension. - Hepatic function: assess liver enzymes before initiation and periodically during therapy. - Drug interactions: review concomitant medications that affect calcium channel activity or hepatic metabolism. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nimotop can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nimodipine plasma levels and risk of toxicity. - Concurrent use with other potent vasodilators (e.g., nitroglycerin): can cause additive hypotensive effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic concentrations. - Beta‑blockers or other antihypertensives: require blood pressure monitoring to avoid excessive lowering. - Antacids containing aluminum or magnesium: may affect absorption; separate administration by at least 2 hours.